Drug Profile


Alternative Names: Active-site inactivated factor VIIa; DEG-Factor VIIa

Latest Information Update: 21 Sep 2000

Price : $50

At a glance

  • Originator Unknown
  • Developer Novo Nordisk; ZymoGenetics
  • Class Thrombolytics
  • Mechanism of Action Factor VIIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Thrombosis; Vascular restenosis

Most Recent Events

  • 21 Sep 2000 Discontinued-Preclinical for Vascular restenosis in Europe (IV)
  • 21 Sep 2000 Discontinued-Preclinical for Coronary artery restenosis in Europe (IV)
  • 21 Sep 2000 Discontinued-Preclinical for Thrombosis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top